Cargando…

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy

The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonparametric population pharmacokinetic modeling, and Monte Car...

Descripción completa

Detalles Bibliográficos
Autores principales: Karvaly, Gellért Balázs, Karádi, István, Vincze, István, Neely, Michael N., Trojnár, Eszter, Prohászka, Zoltán, Imreh, Éva, Vásárhelyi, Barna, Zsáry, András
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415218/
https://www.ncbi.nlm.nih.gov/pubmed/34478238
http://dx.doi.org/10.1002/prp2.856
_version_ 1783747923038699520
author Karvaly, Gellért Balázs
Karádi, István
Vincze, István
Neely, Michael N.
Trojnár, Eszter
Prohászka, Zoltán
Imreh, Éva
Vásárhelyi, Barna
Zsáry, András
author_facet Karvaly, Gellért Balázs
Karádi, István
Vincze, István
Neely, Michael N.
Trojnár, Eszter
Prohászka, Zoltán
Imreh, Éva
Vásárhelyi, Barna
Zsáry, András
author_sort Karvaly, Gellért Balázs
collection PubMed
description The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonparametric population pharmacokinetic modeling, and Monte Carlo simulation to differentiate adherent patients from partially and nonadherent individuals in a nonrandomized, unicentric, observational study. Sixty‐five subjects were enrolled. Nonparametric, mixed‐effect population pharmacokinetic models of the sums of atorvastatin and atorvastatin lactone concentrations (ATR+ATRL) and of the concentrations of the acid and lactone forms of ATR and its 2‐ and 4‐hydroxylated pharmacologically active metabolites (ATR+MET) were elaborated by including the TDM results obtained in 128 samples collected from thirty‐nine subjects. Monte Carlo simulation was performed based on the elaborated models to establish the probabilities of attaining a specific ATR+ATRL or ATR+MET concentration in the range of 0.002–10 nmol (mg dose)(−1) L(−1) at 1–24 h postdose by adherent, partially adherent, and nonadherent patients. The results of the simulations were processed to allow the estimation of the adherence of further 26 subjects who were phlebotomized at sampling times of 2–20 h postdose by calculating the probabilities of attaining the ATR+ATRL and ATR+MET concentrations measured in these subjects in adherent, partially adherent, and nonadherent individuals. The best predictive values of the estimates of adherence could be obtained with sampling at early sampling times. 61.54% and 38.46% of subjects in the adherence testing set were estimated to be fully and partially adherent, respectively, while in all cases the probability of nonadherence was extremely low. The evaluation of patient adherence to ATR therapy based on pharmacokinetic modeling and Monte Carlo simulation has important advantages over the collection of trough samples and the use of therapeutic ranges.
format Online
Article
Text
id pubmed-8415218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84152182021-09-08 A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy Karvaly, Gellért Balázs Karádi, István Vincze, István Neely, Michael N. Trojnár, Eszter Prohászka, Zoltán Imreh, Éva Vásárhelyi, Barna Zsáry, András Pharmacol Res Perspect Original Articles The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonparametric population pharmacokinetic modeling, and Monte Carlo simulation to differentiate adherent patients from partially and nonadherent individuals in a nonrandomized, unicentric, observational study. Sixty‐five subjects were enrolled. Nonparametric, mixed‐effect population pharmacokinetic models of the sums of atorvastatin and atorvastatin lactone concentrations (ATR+ATRL) and of the concentrations of the acid and lactone forms of ATR and its 2‐ and 4‐hydroxylated pharmacologically active metabolites (ATR+MET) were elaborated by including the TDM results obtained in 128 samples collected from thirty‐nine subjects. Monte Carlo simulation was performed based on the elaborated models to establish the probabilities of attaining a specific ATR+ATRL or ATR+MET concentration in the range of 0.002–10 nmol (mg dose)(−1) L(−1) at 1–24 h postdose by adherent, partially adherent, and nonadherent patients. The results of the simulations were processed to allow the estimation of the adherence of further 26 subjects who were phlebotomized at sampling times of 2–20 h postdose by calculating the probabilities of attaining the ATR+ATRL and ATR+MET concentrations measured in these subjects in adherent, partially adherent, and nonadherent individuals. The best predictive values of the estimates of adherence could be obtained with sampling at early sampling times. 61.54% and 38.46% of subjects in the adherence testing set were estimated to be fully and partially adherent, respectively, while in all cases the probability of nonadherence was extremely low. The evaluation of patient adherence to ATR therapy based on pharmacokinetic modeling and Monte Carlo simulation has important advantages over the collection of trough samples and the use of therapeutic ranges. John Wiley and Sons Inc. 2021-09-03 /pmc/articles/PMC8415218/ /pubmed/34478238 http://dx.doi.org/10.1002/prp2.856 Text en © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Karvaly, Gellért Balázs
Karádi, István
Vincze, István
Neely, Michael N.
Trojnár, Eszter
Prohászka, Zoltán
Imreh, Éva
Vásárhelyi, Barna
Zsáry, András
A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title_full A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title_fullStr A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title_full_unstemmed A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title_short A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
title_sort pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415218/
https://www.ncbi.nlm.nih.gov/pubmed/34478238
http://dx.doi.org/10.1002/prp2.856
work_keys_str_mv AT karvalygellertbalazs apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT karadiistvan apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT vinczeistvan apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT neelymichaeln apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT trojnareszter apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT prohaszkazoltan apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT imreheva apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT vasarhelyibarna apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT zsaryandras apharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT karvalygellertbalazs pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT karadiistvan pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT vinczeistvan pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT neelymichaeln pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT trojnareszter pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT prohaszkazoltan pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT imreheva pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT vasarhelyibarna pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy
AT zsaryandras pharmacokineticsbasedapproachtothemonitoringofpatientadherencetoatorvastatintherapy